Jill Johnson

Jill Johnson serves as a key procurement professional within the Administration for Strategic Preparedness and Response (ASPR), supporting the agency’s mission to secure and deploy critical medical countermeasures and biomedical infrastructure for national health emergencies. She manages complex acquisitions aligned with rapid-response capabilities, focusing on research and development contracts for biotechnology and life sciences innovations. Her work ensures the timely procurement of diagnostic tools, therapeutic agents, and scalable manufacturing solutions essential to pandemic and biological threat preparedness, operating within the broader framework of the Department of Health and Human Services’ public health security objectives. While specific contractor names are not publicly identifiable in current records, Jill Johnson engages with a diverse ecosystem of R&D-focused firms, including academic spin-offs, biotech startups, and established life sciences contractors with expertise in vaccine development, diagnostic platform innovation, and clinical trial support infrastructure. Her contracting patterns reflect a preference for performance-based, milestone-driven agreements that incentivize innovation and rapid scalability, fostering partnerships with entities capable of meeting stringent FDA and BARDA compliance standards. Jill’s procurement strategy prioritizes broad market access, with 94.1% of her acquisitions conducted under full and open competition. Only 5.9% are set aside for small businesses under FAR 19.5, indicating a targeted but restrained approach to socioeconomic set-asides, consistent with ASPR’s emphasis on securing high-capacity, mission-critical capabilities from the most qualified providers regardless of size. This reflects a balance between promoting competition and ensuring operational readiness through proven technical capability. Her primary procurement focus lies in NAICS 541714—Research and Development in Biotechnology—accounting for 75% of her activity, with an additional 25% in NAICS 541715 for broader life sciences R&D. She routinely procures preclinical and clinical-stage therapeutics, novel vaccine platforms, point-of-care diagnostics, and scalable biomanufacturing systems, demonstrating deep expertise in the technical and regulatory demands of biomedical innovation procurement.